Next important steps for the new Oncology business area
Per Hagmar, MSc, PhD, appointed Senior Vice President Oncology and Business Development and Håkan Ahlström, Professor, M.D, one of the Antaros Medical founders, will expand his role as Senior Medical Advisor in Oncology.
As part of Antaros Medical´s ambition to expand its innovative imaging methodologies and technologies to support sponsors active in oncology drug development, Per Hagmar has been recruited to lead the Oncology business area. Per has over 20 years of experience of business development and drug development, primarily in the cardiovascular and oncology disease areas. Per has held senior line- and project-leadership roles in AstraZeneca over 19 years, such as global product vice president. Since 2014 he has been responsible for the European activities of Vivolux, a Swedish Biotech company focused on new therapies against cancer with two projects in clinical phase.
To further strengthen the Oncology business area, Håkan Ahlström, one of the founders of Antaros Medical, is increasing his active part as Senior Medical Advisor in the daily work. Håkan is an internationally recognised expert, with extensive research and clinical experience within radiology and imaging, with focus on cardio-metabolism and oncology. Håkan will continue as Head Physician at the Department of Radiology at Uppsala University Hospital and as Professor of Radiology at Uppsala University.
Johannes Hulthe, CEO, says “The combination of pioneering imaging methodology, expertise in drug development and a solid understanding of disease pathophysiology has been key for establishing Antaros Medical in the areas of cardiovascular and metabolic diseases. I strongly believe that this combination of skills also can be successful in the field of oncology. Given Per´s solid background in drug development, with a special focus on oncology I am convinced he is the right person to lead the efforts in this new business area. I am also very pleased to have Håkan as medical lead in this important investment. His expertise within oncology imaging will be invaluable as we continue to build our oncology business area.”
Antaros Medical and Oncology:
- Improved Precision: improved power in clinical trials translating into fewer patients or improved efficacy assessment
- Integrated PET/MRI: complementary information and assessment of tumor heterogeneity and tumor burden
- PET tracer development: for measurement of important checkpoint- and proliferation markers in the tumor, without using biopsy
For more information about this media release, please contact: Johannes Hulthe at firstname.lastname@example.org